This trial is active, not recruiting.

Condition breast cancer
Treatments high dose boost, boost
Phase phase 3
Sponsor The Netherlands Cancer Institute
Start date July 2004
End date December 2015
Trial size 2400 participants
Trial identifier NCT00212121, 2003-13, M03RBC-young boost


hypothesis: 10 Gy additional boost to the tumor bed will yield an increase in local control at 10 years from 88% to 93%, with still acceptable cosmesis.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(Active Comparator)
low dose boost (16 Gy)
high dose boost
high dose boost
low dose versus high dose
high boost (26 Gy)
high dose boost
high dose boost
low dose versus high dose

Primary Outcomes

Local control at 10 yr
time frame: at every follow up visit (< 2 months after last radiation treatment and thereafter yearly

Secondary Outcomes

Cosmetic outcome
time frame: prior to radiotherapy, 1 year after radiotherapy and thereafter every 3 years

Eligibility Criteria

Female participants from 18 years up to 50 years old.

Inclusion criteria: - Age 50 years or younger. - Histological diagnosis of invasive mammary cancer including all subtypes of invasive adenocarcinoma. - Tumor location and extension imaged prior to surgery using at least mammography and ultrasound. - Unicentric tumors and multifocal tumors removed using a wide local excision; microscopic radical resection (focally involved margins allowed, defined as: any DCIS or invasive carcinoma in 3 or fewer low-power fields (using a x 4 objective and a x 10 ocular lens, which has a diameter of 5 mm per low-power microscopic fields). - Sentinel lymph node biopsy and/or axillary lymph node dissection has been performed. - Breast cancer stage: pT1-2pN0-2a M0. - No treatment is allowed prior to surgery (no neoadjuvant chemotherapy, no neoadjuvant hormonal therapy, no pre-operative radiotherapy). - In cases where no adjuvant chemotherapy is given, wide local excision has been performed < 10 weeks before the start of radiotherapy. - In cases where adjuvant chemotherapy is given immediately after surgery, wide local excision has been performed < 6 months before the start of radiotherapy, and chemotherapy should be completed < 6 weeks before the start of radiotherapy. - In cases where hormonal treatment is planned, this is given after completion of the radiotherapy. - No previous history or synchronous malignant tumor in the other breast, previous history of malignant disease, except adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin. - ECOG performance scale 2 or less. Exclusion criteria: - Residual microcalcifications on mammogram. - All histological types of malignancies other than invasive adenocarcinoma. - In situ carcinoma of the breast, without invasive tumor. - Concurrent pregnancy. - Multicentric tumors, and multifocal. tumors excised using multiple excisions * Invasive breast cancer in both breasts.

Additional Information

Official title Radiation Dose Intensity Study in Breast Cancer in Young Women: a Randomized Phase III Trial of Additional Dose to the Tumor Bed
Description Title of the study: Radiation dose intensity study in breast cancer in young women: a randomized phase III trial of additional dose to the tumor bed. Background and aim of the study: Several studies showed that breast conserving therapy (BCT) yields similar survival rates as mastectomy. BCT consists of lumpectomy followed by whole breast radiotherapy (WBRT). Three studies showed that an additional dose to the tumor bed, after 50 Gy WBRT, reduces the local recurrence rate (LRR). The largest of these 3 studies was a recent EORTC trial, which also showed that young age was an independent risk factor for LR after BCT. In patients < 51 years of age, the LR rate was reduced with 50% after a 66 Gy dose to the tumor bed, compared to 50 Gy (5-year LRR 12% vs 5.9%, p < 0.02). However, the LRR in young women was still quite high (> 1% per year). Therefore the first aim of the study is to investigate whether an additional boost dose to the tumorbed (26 Gy) reduces the LRR further. Therefore, we will compare the effect of a low boost dose (16 Gy) with the effect of a high boost dose (26 Gy) on the LRR, but also on the cosmetic outcome. The second, very important aim of this study is to investigate whether we can find genetic or protein profiles that correlate with LRR, lymph node metastases, distant metastases, survival, radiosensitivity, and age. For this purpose we will obtain frozen tumor material and blood samples of as many patients as possible. Population, study design, intervention: Patients younger than 51 years of age, with stage T1-2N01-2aM0 breast cancer, and where the tumor can be locally excised with acceptable cosmetic result, will be randomized between a 16 Gy boost dose to the tumorbed and a 26 Gy boost dose to the tumor bed, after 50 Gy WBRT. Patients will be stratified based on age, tumor size, lymph node metastases, estrogen receptor status, interstitial or external boost irradiation, and institution. In principle frozen tumor samples and blood samples will be stored of each patient. Endpoints and statistics: The primary endpoint is LRR are 10 years. The secondary endpoint is cosmetic result, which will be quantified using digitized color photographs. In addition, patients will be asked to give their opinion about the cosmetic result using standardized questionnaires. To find an increase in the local control rate of 88% to 93% at 10 year, with a power of 80% and a significance level of 5%, 580 patients will be included in each treatment arm. Side studies: An extremely important aspect of this trial is to obtain fresh tumor material and blood samples. These will be used to determine genetic and protein profiles aimed at finding subgroups based on these profiles, which may take more or less advantage of the additional radiation treatment.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by The Netherlands Cancer Institute.